Streetbeat News

Analyst Ratings

CMA

Argus Research analyst Kevin Heal maintains a 'Buy' rating on Comerica (NYSE:CMA) and raises the price target from $56 to $64.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 3:45 pm

DUK

Duke Energy's (NYSE:DUK) short percent of float has risen 12.9% since its last report, with 8.05 million shares sold short, which is 1.05% of all regular shares available for trading. It would take traders 2.48 days to cover their short positions on average. An increase in short interest can signal that investors have become more bearish. Duke Energy's peer group average for short interest as a percentage of float is 2.25%, which means the company has less short interest than most of its peers.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 3:45 pm

DHR

Danaher's (NYSE:DHR) short percent of float has fallen 4.76% since its last report, with 3.97 million shares sold short, which is 0.6% of all regular shares available for trading. This decrease in short interest could signal a more bullish sentiment towards the stock. Compared to its peers, Danaher has less short interest.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 3:45 pm

ELV

Elevance Health's (NYSE:ELV) short percent of float has fallen 11.69% since its last report, with 1.62 million shares sold short, which is 0.68% of all regular shares available for trading. This decrease in short interest could signal a more bullish market sentiment towards the stock. Compared to its peers, Elevance Health has less short interest as a percentage of float, with an average of 3.54%.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 3:45 pm

ROP

Argus Research analyst John Eade maintains a 'Buy' rating on Roper Techs (NASDAQ:ROP) and raises the price target from $490 to $550.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 3:43 pm

MRK

MRNA

William Blair initiated coverage on Moderna Inc (MRNA) with a Market Perform rating, establishing a fair value estimate of $136.28 per share. The valuation considers the declining COVID-19 base business, the competitive ex-COVID vaccine landscape, and the timing gap to the early-stage therapeutic pipeline. The firm models around $6.3 billion in global COVID-19 vaccine revenue in 2023. Moderna's personalized cancer vaccine (PCV), developed in partnership with Merck & Co Inc (MRK), has shown positive results in Phase 2 trials and is advancing to Phase 3.

Portfolio Pulse from Vandana Singh

July 24, 2023 | 3:39 pm

LYV

Evercore ISI Group analyst David Joyce maintains an In-Line rating on Live Nation Entertainment (NYSE:LYV) and raises the price target from $90 to $100.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 3:35 pm

SCHW

Piper Sandler analyst Patrick Moley maintains an Overweight rating on Charles Schwab (NYSE:SCHW) and raises the price target from $77 to $86.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 3:32 pm

WBD

Evercore ISI Group analyst Vijay Jayant has maintained an 'Outperform' rating on Warner Bros. Discovery (NASDAQ:WBD) but lowered the price target from $25 to $20.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 3:31 pm

ADBE

A significant investor has taken a bullish stance on Adobe (NASDAQ:ADBE), with 50% of investors opening trades with bullish expectations and 50% with bearish. Of the total trades, 8 are puts amounting to $645,330 and 6 are calls amounting to $296,309. The targeted price range for Adobe over the last 3 months is from $430.0 to $630.0. The current price of ADBE is up 0.42% at $522.41, with RSI indicators suggesting it may be approaching overbought. Next earnings are expected in 52 days.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 3:30 pm